Skip to main content

Advertisement

Log in

Safety of bevacizumab 7.5 mg/kg infusion over 10 minutes in NSCLC patients

  • SHORT REPORT
  • Published:
Investigational New Drugs Aims and scope Submit manuscript

Summary

Background Bevacizumab is a humanized IgG1 monoclonal antibody against VEGF. Because infusion-related hypersensitivity reactions (HSRs) are a concern with monoclonal antibodies, initial phase 1 trials used a 90-, 60-, then 30-min initial infusion sequence. We evaluated the impact of a shortened bevacizumab infusion (10 min) on toxicity in nonsmall cell lung cancer (NSCLC) patients. Patients and methods Consecutive patients with stage IV NSCLC eligible for anti-VEGF therapy received a platinum doublet plus bevacizumab 7.5 mg/kg infused over 10 min, every 3 weeks, in the outpatient setting. Blood pressure was monitored at home twice daily, and other toxicities (HSRs and proteinuria) were monitored at each treatment administration. Results Bevacizumab was given as a 10 min infusion in 55 patients (group A), and using the standard sequence in another 36 patients (group B). Hypertension (grade ≥2) was observed in 18/55 (32.7%) patients in group A and 13/36 (38.9%) patients in group B (p = 0.77). Similarly, no difference was seen regarding the incidence of grade ≥2 proteinuria (12.7% vs. 19.4%, p = 0.39), arterial thrombo-embolic events (0 in each group) or venous thromboembolic events (1.8% vs. 8.3%, p = 0.29). Conclusions Our data suggest that bevacizumab 7.5 mg/kg can be safely infused over 10 min in unselected NSCLC patients despite their cardio-vascular and respiratory comorbidities, saving time for both patients and caregivers.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A, Lilenbaum R, Johnson DH (2006) Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 355(24):2542–2550. doi:355/24/2542

    Article  CAS  PubMed  Google Scholar 

  2. Gordon MS, Margolin K, Talpaz M, Sledge GW Jr, Holmgren E, Benjamin R, Stalter S, Shak S, Adelman D (2001) Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer. J Clin Oncol 19(3):843–850

    CAS  PubMed  Google Scholar 

  3. Margolin K, Gordon MS, Holmgren E, Gaudreault J, Novotny W, Fyfe G, Adelman D, Stalter S, Breed J (2001) Phase Ib trial of intravenous recombinant humanized monoclonal antibody to vascular endothelial growth factor in combination with chemotherapy in patients with advanced cancer: pharmacologic and long-term safety data. J Clin Oncol 19(3):851–856

    CAS  PubMed  Google Scholar 

  4. Reidy DL, Chung KY, Timoney JP, Park VJ, Hollywood E, Sklarin NT, Muller RJ, Saltz LB (2007) Bevacizumab 5 mg/kg can be infused safely over 10 minutes. J Clin Oncol 25(19):2691–2695. doi:25/19/2691

    Article  CAS  PubMed  Google Scholar 

  5. Coriat R, Mir O, Chaussade S, Goldwasser F (2010) Safety of 10 min infusion of bevacizumab in combination with 5FU-based chemotherapy in non-selected metastatic colorectal cancer patients. Dig Liver Dis 43(3):248–249. doi:S1590-8658(10)00351-8

    Article  PubMed  Google Scholar 

  6. Dohn LH, Jensen BV, Larsen FO (2010) Short time infusion of bevacizumab in combination with 5FU-based chemotherapy as first-line therapy in a non-selective patient group with metastatic colorectal cancer. Acta Oncol 49(3):395–396. doi:10.3109/02841860903428184

    Article  CAS  PubMed  Google Scholar 

  7. Mahfoud T, Tanz R, Mesmoudi M, Khmamouche MR, Bazine A, Aassab R, Ismaili N, Boutayeb S, Ichou M, Errihani H (2010) Bevacizumab 5 or 7.5 mg/kg in Metastatic colorectal cancer can be infused safely over 10 minutes. J Gastrointest Cancer. doi:10.1007/s12029-010-9245-x

  8. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A, Griffing S, Holmgren E, Ferrara N, Fyfe G, Rogers B, Ross R, Kabbinavar F (2004) Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350(23):2335–2342. doi:10.1056/NEJMoa032691

    Article  CAS  PubMed  Google Scholar 

  9. Durand JP, Madelaine I, Scotte F (2009) Guidelines for prophylaxis and treatment of chemotherapy-induced nausea and vomiting. Bull Cancer 96(10):951–960. doi:bdc.2009.0924

    CAS  PubMed  Google Scholar 

  10. Cobleigh MA, Langmuir VK, Sledge GW, Miller KD, Haney L, Novotny WF, Reimann JD, Vassel A (2003) A phase I/II dose-escalation trial of bevacizumab in previously treated metastatic breast cancer. Semin Oncol 30(5 Suppl 16):117–124. doi:S0093775403004469

    Article  CAS  PubMed  Google Scholar 

Download references

Conflict of interest

The authors declare no conflicts of interest.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Olivier Mir.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Mir, O., Alexandre, J., Coriat, R. et al. Safety of bevacizumab 7.5 mg/kg infusion over 10 minutes in NSCLC patients. Invest New Drugs 30, 1756–1760 (2012). https://doi.org/10.1007/s10637-011-9690-9

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10637-011-9690-9

Keywords

Navigation